TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03014050

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: e-Tapper TT-R1
Description: The e-Tapper is a non-invasive, handheld electronic device designed to apply micro current stimulation to a person's hands at specified points representing various body parts, such as the head, leg, or foot. This is one form of Bio-Electro Stimulation Therapy known as the 11-point Hand Treatment System. The current delivered is less than one milliampere.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: e-Tapper TT-R1
Description: The e-Tapper is a non-invasive, handheld electronic device designed to apply micro current stimulation to a person's hands at specified points representing various body parts, such as the head, leg, or foot. This is one form of Bio-Electro Stimulation Therapy known as the 11-point Hand Treatment System. The current delivered is less than one milliampere.
Study: NCT03107286

Intervention type: DRUG
Intervention: Tc-99M-MAG3
Description: Participants will be asked to be imaged at an additional time point during a nuclear medicine study using Tc-99m MAG3

Intervention type: OTHER
Intervention: Modification in acquisition protocol
Description: Participants will be asked to be imaged at an additional time point.
Study: NCT03591809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined exercise training
Description: The combined exercise training group will be given combined exercise training, consisting of Pilates and aerobic exercise, three times during 8 weeks.
Study: NCT03036735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: steroid eluting spacer
Description: The Restora Mometasone Furate Eluting Spacer will be compared to the Silastic spacer.
Study: NCT00877435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Study: NCT00408928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib at 1.3 mg/m2/dose given twice weekly for two weeks followed by a 10-day rest period. If patients have a complete response, they will receive additional cycles of bortezomib.
Study: NCT02521116

Intervention type: OTHER
Group type: OTHER
Intervention: Dynamic Vessel Analyzer

Intervention type: OTHER
Group type: OTHER
Intervention: Oxymap T1
Study: NCT03990220

Intervention type: DIETARY_SUPPLEMENT
Intervention: Lactobacillus rhamnosus yoba 2012
Description: Probiotics are defined by the Food and Agricultural Organization (FAO)/WHO as live microorganisms, which when consumed in adequate amounts, confer a health benefit on the host. Lactobacillus rhamnosus GG (LGG) is the most documented probiotic bacteria, with many proven unique characteristics and therewith associated health benefits. No adverse effects of the consumption of LGG in healthy infants have been reported. The Lactobacillus rhamnosus yoba containing yoghurt drink, which is locally produced and subsequently consumed by resource-poor communities in rural Uganda has been described. The strain used in this intervention is a generic variant of LGG, called Lactobacillus rhamnosus yoba 2012. LGG is consumed as part of food all over the world, and is not a drug.
Study: NCT00518557

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter Arterial Chemoembolization
Description: The interventional procedure is performed as following steps: 1)transcatheter hepatic arterial angiography(including any feeding arteries to the tumor) is performed under a DSA unit; 2) super selectively catheterizaton of feeding arteries to the tumor is reached; 3)30 mg of Andostatin (Simcere Co. China) mixtured with 5 ml Lipiodol is injected into the tumor via the feeding arteries; 4) followed by 10 mg of Epifubicin mixtured with 5 ml of Lipiodol; 5) All feeding arteries to the tumor are occluded which is confirmed by re-angiography.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter Arterial Chemoembolization
Description: The interventional procedure is performed as following steps: 1)transcatheter hepatic arterial angiography(including any feeding arteries to the tumor) is performed under a DSA unit; 2) super selectively catheterizaton of feeding arteries to the tumor is reached; 3)30 mg of Andostatin (Simcere Co. China) mixtured with 5 ml Lipiodol is injected into the tumor via the feeding arteries; 4) followed by 10 mg of Epifubicin mixtured with 5 ml of Lipiodol; 5) All feeding arteries to the tumor are occluded which is confirmed by re-angiography.
Study: NCT00048828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Participants will receive olanzapine for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clozapine
Description: Participants will receive 12 weeks of clozapine.
Study: NCT02655380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 1
Description: Anesthesia induction is performed with 1 mg ketamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 2
Description: Anesthesia induction is performed with 2 mg ketamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: After anesthesia induction with ketamine, predetermined remifentanil using Dixon's up and dowm method is administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: After anesthesia induction with ketamine, predetermined remifentanil using Dixon's up and dowm method is administered.
Study: NCT02438124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation
Description: The subjects are submitted in one hearing stimulus while they realize a walking test

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation
Description: The subjects are submitted in one hearing stimulus while they realize a walking test
Study: NCT00470106

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive remediation
Description: Computer exercises in attention, memory, and speed of processing.
Study: NCT00548886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: We will follow the protocol outlined by Ackerman et al. known as the Mayo protocol4 which is currently used routinely in our electrophysiology laboratory. Epinephrine infusion will begin at 0.025 ug/kg/minute, for ten minutes and a twelve-lead electrocardiogram is obtained at time=0 minutes, 5 minutes, and 10 minutes. The epinephrine infusion will then be increased to 0.05 ug/kg/minute for five minutes and the electrocardiogram repeated. The epinephrine infusion will then be increased to a maximal dose of 0.1 ug/kg/minute for five minutes and electrocardiogram obtained. The epinephrine infusion is then discontinued and measurements are obtained at five minutes and ten minutes after stopping the epinephrine infusion. The total time of procedure will be 35 minutes.
Study: NCT04513236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-survey incentive
Description: An incentive of is given in the form of airtime to motivate participants to complete the survey. Participants were sent 0.1X before the were sent a mobile phone survey and an additional 1X after completing the survey.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-survey incentive
Description: An incentive in the form of airtime to motivate participants to complete the survey. Participants were given Bangladeshi Taka or Ugandan Shillings worth of certain airtime for completing the survey.
Study: NCT03404882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive/reminder text messaging plus peer support
Description: Regular supportive/reminder text message will be delivered to patients who will also receive face to face and interactive text message support from peer support workers

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive/reminder text messaging
Description: Regular supportive/reminder text message will be delivered to patients who will NOT receive any face to face or interactive text message support from peer support workers

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer support only
Description: face to face support from peer support workers but no interactive or daily supportive/reminder text messages
Study: NCT03735914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Neuralgic patients for which a cryoneurolysis has been indicated, will passed an MRI befor and after the cryoneurolysis to check the presence of the nerve.
Study: NCT04203576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FIRE1 System
Description: FIRE1 System
Study: NCT01741961

Intervention type: PROCEDURE
Intervention: Ahmed valve
Description: The flexible plate 7 (FP7) model (New World Medical) was implanted in patients with uncontrolled glaucoma.
Study: NCT02476227

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation using CARTO system
Description: automated algorithm (Visitag)-based vs. manual collection of RF ablation points during AF ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation using CARTO system
Description: automated algorithm (Visitag)-based vs. manual collection of RF ablation points during AF ablation
Study: NCT05119816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy intervention
Description: Received a customize playlists prepared by a certified music therapist to listening to during KB
Study: NCT03680521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib oral capsule administered daily for 6-8 weeks in segments 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab administered as 240 mg IV every 2 weeks for 4-6 weeks in segment 2.
Study: NCT02576626

Intervention type: DRUG
Group type: OTHER
Intervention: indacaterol/glycopyrronium 110/50 Breezhaler®

Intervention type: DRUG
Group type: OTHER
Intervention: indacaterol/glycopyrronium 110/50 Breezhaler®

Intervention type: DEVICE
Group type: OTHER
Intervention: Placebo by Breezhaler®

Intervention type: DEVICE
Group type: OTHER
Intervention: Placebo by Breezhaler®

Intervention type: DRUG
Group type: OTHER
Intervention: ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation

Intervention type: DRUG
Group type: OTHER
Intervention: ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation

Intervention type: DEVICE
Group type: OTHER
Intervention: Placebo by nebulisation

Intervention type: DEVICE
Group type: OTHER
Intervention: Placebo by nebulisation
Study: NCT04470414

Intervention type: DIAGNOSTIC_TEST
Intervention: IgG antibodies immunoassay
Description: Assessment of IgG level will be done by quantitative assessment of IgG in the serum of recovered persons by Chemiluminescence Immunoassay (CLIA).
Study: NCT02321475

Intervention type: DRUG
Intervention: EGb761®
Study: NCT04541615

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Online course with proficiency test
Description: Participants will receive an online e-course with a proficiency test at the end. Afterwards, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Online course
Description: Participants will receive an online e-course but are not required to pass the proficiency test. Afterwards, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard training group
Description: After receiving a traditional lecture, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apprenticeship group
Description: Participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end. Participants will only receive papers on how the task will be performed and clinicians will help them with completion of the task.
Study: NCT01239940

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angioplasty using the paclitaxel-eluting balloon
Description: Balloon angioplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angioplasty using the Everolimus-eluting stent
Description: Stent implantation
Study: NCT03542617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Solution
Study: NCT01021527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment A
Description: No Treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment A
Description: No Treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment A
Description: No Treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment A
Description: No Treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment A
Description: No Treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment A
Description: No Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment B
Description: single dose administration of exenatide 5ug by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment B
Description: single dose administration of exenatide 5ug by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment B
Description: single dose administration of exenatide 5ug by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment B
Description: single dose administration of exenatide 5ug by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment B
Description: single dose administration of exenatide 5ug by subcutaneous injection
Study: NCT00762385

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: galyfilcon A
Description: galyfilcon A

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: galyfilcon A
Description: galyfilcon A

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: comfilcon A

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: comfilcon A
Study: NCT01824875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO
Study: NCT01274078

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blueberries
Description: 150 grams of frozen blueberries on the same day as exercise
Study: NCT01390129

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: Deflated blood pressure cuff placed on upper arm for 30min

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated before aortic clamping and repeated 3 times in total
Study: NCT02000583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic group participants will engage in 150 minutes of aerobic exercise over 4-5 days per week for 52 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Control group participants will be provided educational materials on starting an exercise program, but will receive no formal support for their exercise program.
Study: NCT00470106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognitive skills training
Description: Group training on emotion perception, social perception, and understanding others' mental states.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: hybrid intervention
Description: A combination of the two groups listed above.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: skills training
Description: Skills training in how to identify symptoms of illness and medication side effects.
Study: NCT02170636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Capsule E
Description: 50 mg BIBR 1048 MS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Capsule E
Description: 50 mg BIBR 1048 MS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Capsule F
Description: 50 mg BIBR 1048 MS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Capsule G
Description: 50 mg BIBR 1048 MS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Tablet H
Description: 50 mg BIBR 1048 MS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Tablet H
Description: 50 mg BIBR 1048 MS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Drinking solution
Description: 50 mg BIBR 1048 MS tartaric acid solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Drinking solution
Description: 50 mg BIBR 1048 MS tartaric acid solution
Study: NCT02138981

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemoembolization and Response-Dependent Resection
Description: patients underwent transarterial chemoembolization (TACE) as initial treatments, and only patients who showed good response were subjected to surgical resection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Resection
Description: patients received immediate surgical resection.
Study: NCT00707447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREDIAS
Description: Group programme aiming at modification of lifestyle: lifestyle changes, 12 lesson a 90 minutes, delivered in a group setting, consists of analysis of barriers against lifestyle changes, behavior analysis of eating and exercise behavior, modification of unhealthy lifestyle and relapse prevention

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Written Information about diabetes risks. Brochure about the value of a healthy lifestyle, calorie table, suggestions for healthy food and daily exercise
Study: NCT01115855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: Eplerenone 25 mg once every other day, 25mg once daily or 50 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily or every once daily
Study: NCT01279655

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS
Description: 20 min, 1mA, 8 weeks (5 days a week, 20 min a day)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: 20 min, 1mA, 8 weeks (5 days a week, 20 min a day)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Bimanual Training
Description: The training program consisted of a bimanual etch-a-sketch task. By rotating two wheels subjects have to match a line presented on the screen with the cursor. 8 weeks (5 days a week, 20 min a day)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bimanual Training
Description: The training program consisted of a bimanual etch-a-sketch task. By rotating two wheels subjects have to match a line presented on the screen with the cursor. 8 weeks (5 days a week, 20 min a day)
Study: NCT00466804

Intervention type: PROCEDURE
Intervention: Heart transplant
Description: People in this study will have a heart transplant and be monitored for signs of rejection
Study: NCT02845726

Intervention type: OTHER
Intervention: Stent examination, urinary analysis, USSQ questionnaire
Study: NCT04239482

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arginine + Nitrate / Nitrite
Description: Longer-term supplementation (8 weeks)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Longer-term supplementation (8 weeks)
Study: NCT01658202

Intervention type: DRUG
Group type: OTHER
Intervention: V0116 transdermal patch (Test treatment )

Intervention type: DRUG
Group type: OTHER
Intervention: V0116 transdermal patch (Test treatment )

Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine transdermal patch (Reference Treatment )
Study: NCT02170636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 40 mg Pantoprazole
Study: NCT01689519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo supplied as tablets
Study: NCT01658202

Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine transdermal patch (Reference Treatment )
Study: NCT03652831

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soft Tissue Mobilization with Neural Mobilization
Description: Cervical Traction for 15mints 7%of body weight with 7 second hold time and 5 second rest time.~* Hot Pack for 10mints~* Post isometric relaxation technique. The post-isometric relaxation technique begins by placing the muscle in a stretched position. Then an isometric contraction is exerted against minimal resistance. Relaxation and then gentle stretch follow as the muscle releases. Frequency for PIRs 3sets of 5 repetitions and duration of 10minute.~* Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization.~Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 15minute. Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 50mints each session)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soft Tissue Mobilization without Neural Mobilization
Description: * Cervical Traction for 15mints 7%of body weight with 7 second hold time and 5 second rest time.~* Hot Pack for 10mints~* Post isometric relaxation technique. The post-isometric relaxation technique begins by placing the muscle in a stretched position. Then an isometric contraction is exerted against minimal resistance. Relaxation and then gentle stretch follow as the muscle releases. Frequency for PIRs 3sets of 5 repetitions and duration of 10minutes Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 35mints each session)